BullFrog AI Holdings, Inc.
For the period ended Apr 13, 2026. Filed Apr 13, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Apr 13, 2026 · Filed Apr 13, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · A COMPLETE, DIFFERENTIATED AI PLATFORM
A COMPLETE, DIFFERENTIATED AI PLATFORM
With the March 2026 launch of bfARENAS™, we believe BullFrog AI now offers the only fully integrated end-to-end AI platform purpose-built for pharmaceutical R&D — spanning the complete journey from raw data to strategic decision:
bfPREP™ harmonizes complex, fragmented biomedical data into structured, AI-ready assets — compressing data preparation timelines from months to days and creating a reliable foundation for downstream analysis.
bfLEAP® applies causal network inference and machine learning to identify drug targets, patient subgroups, and disease drivers from multimodal datasets — generating explainable insights built to withstand scientific and regulatory scrutiny.
bfARENAS™ translates biological insight into ranked, defensible portfolio and clinical trial design decisions evaluated across multiple strategic scenarios — directly addressing one of the industry’s most persistent decision-making failure modes.
Enterprise pharmaceutical organizations seek to adopt AI at scale within their existing infrastructure — not integrate a patchwork of point solutions. Our platform aims to meet them where their data lives, and our recent commercial agreement demonstrates validation of our fully integrated stack.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.